These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 22245806)

  • 1. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
    Mariz JM; Esteves GV
    Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
    Palumbo A; Dimopoulos M; San Miguel J; Harousseau JL; Attal M; Hussein M; Knop S; Ludwig H; von Lilienfeld-Toal M; Sonneveld P
    Blood Rev; 2009 Mar; 23(2):87-93. PubMed ID: 18774632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide: an update on evidence from clinical trials.
    Dimopoulos MA; Terpos E
    Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
    Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R
    Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of thalidomide in multiple myeloma.
    Schwab C; Jagannath S
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
    Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
    Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
    Tariman JD
    Clin J Oncol Nurs; 2007 Aug; 11(4):569-74. PubMed ID: 17723971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of plasma cell dyscrasias with lenalidomide.
    Dimopoulos MA; Kastritis E; Rajkumar SV
    Leukemia; 2008 Jul; 22(7):1343-53. PubMed ID: 18509355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide in the treatment of multiple myeloma.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
    Scott LJ; Lyseng-Williamson KA
    BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How lenalidomide is changing the treatment of patients with multiple myeloma.
    Dimopoulos MA; Terpos E; Niesvizky R
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
    Niesvizky R; Naib T; Christos PJ; Jayabalan D; Furst JR; Jalbrzikowski J; Zafar F; Mark T; Lent R; Pearse RN; Ely S; Leonard JP; Mazumdar M; Chen-Kiang S; Coleman M
    Br J Haematol; 2007 Sep; 138(5):640-3. PubMed ID: 17686058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
    Larocca A; Cavallo F; Mina R; Boccadoro M; Palumbo A
    Future Oncol; 2012 Oct; 8(10):1223-38. PubMed ID: 23130924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide: patient management strategies.
    Hussein MA
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S22-5. PubMed ID: 16344098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.